Overview

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as dulaglutide when added to sodium-glucose co-transporter 2 (SGLT2) inhibitors in participants with type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Canagliflozin
Dapagliflozin
Dulaglutide
Empagliflozin
Immunoglobulin Fc Fragments
Metformin
Sodium-Glucose Transporter 2 Inhibitors